StockData

Invivyd vs Protalix BioTherapeutics

IVVD and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IVVD and PLX compare

Protalix BioTherapeutics is the larger company, worth 1.5 times as much as Invivyd ($232M against $151M).

Protalix BioTherapeutics grew revenue faster over the last twelve months (30.1% versus 26.3% for Invivyd).

Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with −184% at Invivyd.

Protalix BioTherapeutics scores higher on the StockData Score (16 against 9 for Invivyd), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIVVDPLX
Size and price
Market cap$151M$232M
Share price$0.513$2.88
Change, 1 year−78.2%54.8%
Change, 5 years−98.0%191%
Beta (5Y)2.531.40
Employees122226
StockData Score
Total score916 (better)
Valuation score34 (better)
Growth score12 (better)
Performance score04 (better)
Health score56 (better)
Dividend score00
Valuation
P/E–12.5×
P/S2.6× (better)2.9×
P/B0.8× (better)3.2×
EV/EBITDA–8.8×
P/FCF–30.3×
FCF yield−72.6%3.3% (better)
Fair value$0.978$5.38
Margin of safety47.6% (better)46.5%
Growth
Revenue growth (TTM)26.3%30.1% (better)
Revenue growth, 5Y average–−3.5%
Net income growth (TTM)–202%
EPS growth (TTM)–475%
Profitability
Gross margin–69.2%
Operating margin−193%28.9% (better)
Net margin−184%23.5% (better)
FCF margin−188%9.5% (better)
Return on equity−95.9%31.2% (better)
Return on invested capital−616%49.5% (better)
Financial health
Debt / equity0.000.00
Current ratio5.87 (better)2.94
Altman Z-score−4.865.67 (better)
Piotroski F-score5 (better)4
Dividends and buybacks
Buyback yield−0.26%–
Shareholder yield−0.26%0.00% (better)
Ownership
Held by institutions79.0%17.9%
Held by insiders16.7%3.8%
Insider net buying, 12 months−$531K$101K (better)
Short interest, % of float14.7%4.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.